Jack Davis, Diagnostics Industry Executive, Joins the HistoRx, Inc. Board of Directors
12/15/2010 11:13:53 AM
BRANFORD, Conn., Dec. 15, 2010 /PRNewswire/ -- HistoRx announces that Jack Davis has accepted its invitation to join the Board of Directors. As the former President and CEO of both a diagnostic product company and a laboratory testing company, he is an acknowledged diagnostic industry expert.
Mr. Davis was Co-founder, President, CEO and eventually Chairman of the Board at Dianon Systems, a leading provider of specialized clinical laboratory and anatomic pathology testing services and disease management systems focusing on cancer, pre-natal genetics and cytogenetics. Dianon Systems was sold to LabCorp in 2002. In addition, he served as President and CEO of Calypte Biomedical, a biodiagnostics company that developed the first urine-based HIV test, where he shepherded the company through its IPO. Previously, he was Division Vice President and worldwide General Manager of Abbott Laboratories Diagnostics Products business unit.
HistoRx CEO Rana K. Gupta approached Mr. Davis with the opportunity, commenting, "Now that HistoRx has proven our license model for diagnostics commercialization, it's crucial to expand our expertise in both the laboratory services business and the diagnostic product arena since these are the avenues of distribution we will continue to pursue. Jack's experience with running Abbott's worldwide Diagnostics Products business and with building a national anatomic pathology services business at Dianon make him a valuable addition to the HistoRx Board."
"I'm delighted to join the board of directors of HistoRx, a company that, working with the Pathology community at large, is committed to improving the objectivity, reproducibility and quantitation of anatomic pathology," Davis stated. "Testing services based on AQUA technology are improving the quality of care in cancer diagnostics."
About HistoRx (www.historx.com)
HistoRx, Inc. is a leading developer of tissue-based theranostic solutions to advance individualized patient care. The Company's products and services are based on proprietary AQUA® technology for tissue biomarker analysis. AQUA® software is the only platform capable of precisely measuring protein biomarker concentration with sub-cellular resolution in tissue sections, enabling fully objective, standardized, reproducible, and automated analysis to guide targeted drug development and therapeutic decision making. HistoRx currently helps biopharmaceutical companies advance their product pipelines by generating valuable new insights into the safety and effectiveness of targeted therapeutics in development for cancer and other diseases, and is developing clinical assays based on these insights. For more information please visit www.historx.com.
SOURCE HistoRx, Inc.